MEMarie-Paule Emonds

Marie-Paule Emonds

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marie-Paule Emonds has a total of 501 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multicenter kidney transplantation study identifies hierarchy and directionality of HLA-DQ alloimmune responses

    by Dennis A. J. Van Den Broek, Akansha Agrawal, Marta Crespo, Marie-Paule Emonds, Sebastiaan Heidt, Danny van der Helm, Tobias L. Lenz, Maria Meneghini, Eduard Palou, Dolores Redondo Pachón, et al.

    HLA-incompatibility between recipient and donor is conventionally assessed by counting serologic mismatches. More recently, tools quantifying differences at the amino acid level are advocated to prognosticate risk for generation of de-novo donor-specific antibodies (dnDSA). Using hierarchical clustering based on HLA evolutionary divergence and amino acid physiochemical unique qualities to evaluate HLA-DQ αβ-heterodimers, we demonstrate that HLA-DQ alleles segregate into two main evolutionary clades, and further subdivide into six functional sub-categories. Applying this biologically grounded immune risk-stratification approach to a cohort of 3003 kidney allograft recipients from five transplant centers shows that transplantation across the two evolutionary clades is associated with hierarchy and directionality of humoral immune responses, despite similar values when applying quantitative metrics. Our three-tier risk stratification model identifies patients at higher risk to develop dnDSA (HR:6.77; 95%CI:4.64-9.90), and antibody mediated rejection (HR:4.41; 95%CI:1.44-13.53). This work provides a thoughtful immunologic framework, that outperforms quantitative metrics, for alloimmune risk stratification.

  • Open Access

    Cytomegalovirus Infection Determines Microvascular Inflammation Risk beyond Alloimmunity in Kidney Transplantation

    by Maarten Naesens, Thomas Vanhoutte, Matthias Diebold, Karolien Wellekens, Priyanka Koshy, Jasper Callemeyn, Bertrand Chauveau, Tim Debyser, Steffi De Pelsmaeker, Marie-Paule Emonds, et al.

    Microvascular inflammation (MVI) is a major determinant of kidney allograft failure, yet its upstream drivers remain incompletely defined. Natural killer (NK) cells contribute to donor-specific antibody (DSA)-positive and DSA-negative MVI via antibody-dependent cytotoxicity and missing-self recognition. Cytomegalovirus (CMV) infection durably remodels the NK cell compartment, inducing memory-like populations with heightened effector function. In a contemporary multicenter cohort of 4,411 kidney transplants with 10,214 post-transplant biopsies in the CMV prophylaxis era, CMV seropositivity, indicative of prior infection, was independently associated with a twofold higher hazard of MVI and increased graft failure. This association extended across antibody-mediated and DSA-negative, C4d-negative MVI and acted synergistically with HLA-DSA and missing self. Post-transplant CMV replication and disease were associated with subsequent MVI only in seronegative recipients, consistent with an effect of primary CMV infection. Together, these findings identify CMV infection as a clinically relevant and previously underrecognized determinant of MVI, beyond alloimmune factors.

  • Open Access

    Anti-HLA antibodies in lung transplantation: diagnostic pitfalls and future directions

    by Andrea Zajacova, Eva Revilla-Lopez, Miray Guney, Steffi De Pelsmaeker, Marie-Paule Emonds, Maarten Naesens, Berta Saez-Gimenez, Bart M. Vanaudenaerde, Robin Vos

    Lung transplant recipients face high rejection rates, causing significant disease burden and limiting long-term outcomes. Among immunological factors affecting lung allografts, anti-human leukocyte antigen (HLA) antibodies, particularly donor-specific anti-HLA antibodies (DSAs), are key mediators of antibody-mediated rejection. Yet, the biology, detection and interpretation of DSAs remain incompletely defined across the pre-, peri- and post-transplant continuum. HLAs are highly polymorphic immune recognition molecules, and donor–recipient mismatches drive alloimmune responses. HLA typing is used to assess genetic disparity, but low-resolution approaches risk misclassifying mismatches and DSAs, whereas high-resolution typing improves diagnostic accuracy yet is not universally implemented. Standard HLA antibody monitoring assays report median fluorescence intensity. However, median fluorescence intensity does not convey information on the affinity, avidity or functional capacity of these antibodies, and may be affected by technical factors such as bead saturation, the Hook effect or binding to denatured HLAs. Subclass profiling adds further complexity: IgG1 and IgG3 are potent complement activators, whereas IgG2 and IgG4 have weaker or regulatory roles and differ in clearance by apheresis. Functional assays, including C1q- or C3d-binding HLA antibody detection assays and emerging endothelial or natural killer-cell-based platforms, offer additional insights into antibody-binding, complement activation and cytotoxic potential, but are not routinely applied in current clinical practice. Prospective mechanistic studies are required to define the clinical benefit, cost-effectiveness and optimal integration of these advanced immunological tools into routine practice pre-, peri- and post-lung transplant. DSAs drive lung allograft injury, yet their detection and interpretation remain inconsistent. Implementation of high-resolution HLA typing and functional assays may improve risk assessment and guide future clinical practice.

  • Top Cited Papers
    Open Access

    Continuous indices to assess the phenotypic spectrum of kidney transplant rejection

    by Thibaut Vaulet, Priyanka Koshy, Karolien Wellekens, Olivier Aubert, Charlotte Bottomley, Jasper Callemeyn, Evert Cleenders, Maarten Coemans, Lynn Cornell, Aiko P. J. de Vries, et al.

    The Banff classification for kidney transplant pathology dichotomizes the rejection continuum into distinct diagnostic categories, introducing artificial cutoff points and threshold effects. To better reflect the underlying disease spectrum, in this cohort study of 19,500 biopsies from 8873 patients across 10 centers worldwide, we developed two indices for quantifying antibody-mediated rejection/microvascular inflammation and T-cell-mediated rejection/tubulointerstitial inflammation from histological lesion scores and calculated indices for overall activity and chronicity. These indices demonstrate excellent discrimination for the main diagnostic categories of rejection (AUCs from 0.95 to 0.99), with consistent performance across derivation and validation datasets. These indices strictly confine intermediate phenotypes to low index values and are associated to graft failure even within the diagnostic categories, thus reflecting the underlying rejection continuum. In this work, we demonstrate that four continuous indices provide implementable and interpretable global evaluation of kidney transplant histology that align with the continuous nature of the rejection process regardless of the underlying disease cause.


  • Open Access

    Impact of Solvent-Accessible HLA Amino Acid Mismatches on Kidney Transplant Outcomes: A Multicenter Longitudinal Study

    by Soufian Meziyerh, Suzanne Bezstarosti, Aleksandar Senev, Dennis van Den Broek, Maarten Coemans, Jesper Kers, Teun van Gelder, Danny van der Helm, Paul van der Boog, Johan de Fijter, et al.

    Current alloimmune risk assessment in kidney transplantation relies on HLA antigen mismatches, lacking precision for individualized care. In contrast, solvent-accessible HLA amino acid (saAA) mismatches, empirically defined across all HLA loci, offer a stable and objective alternative. We conducted a multicenter longitudinal study evaluating saAA mismatches, calculated using HLA-EMMA, in relation to key transplant outcomes. Among 2,473 kidney transplant recipients (median follow-up 6.9 years), 36% reached a hierarchical composite endpoint of death-censored graft failure(DCGF), biopsy-proven acute rejection(BPAR), or de novo donor-specific antibody(dnDSA). Multivariable analyses showed total, class I, class II, and locus-specific saAA mismatch scores were significantly associated with the composite outcome, as well as DCGF, BPAR and dnDSA individually (all P<.001). These findings suggest that saAA mismatch load provides a more granular and reproducible measure of alloimmune risk compared to traditional antigen-level mismatches. Incorporating saAA mismatch analysis could enable personalized immunosuppression strategies and optimized transplant monitoring in clinical practice.

  • Open Access

    The impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter study

    by Karolien Wellekens, Maarten Coemans, Priyanka Koshy, Thibaut Vaulet, Evert Cleenders, Tim Debyser, Steffi De Pelsmaeker, Valérie Dubois, Marie-Paule Emonds, Dirk Kuypers, et al.


  • Open Access

    Clinical predictors for restrictive allograft syndrome: A nested case-control study

    by Hanne Beeckmans, Pieterjan Kerckhof, Nilufer Acet Öztürk, Andrea Zajacova, Jan Van Slambrouck, Saskia Bos, Marie Vermant, Lyne O. Van Dieren, Tessa Goeminne, Christelle Vandervelde, et al.


  • Impact of repeat human leukocyte antigen mismatches on kidney graft survival: A contemporary Collaborative Transplant Study analysis

    by Lissa Pipeleers, Christian Unterrainer, Marie-Paule Emonds, Karl Martin Wissing, Thuong Hien Tran


  • Open Access

    Probable antibody-mediated rejection in kidney transplantation is a rare and challenging phenotype to define: Findings from a single-center study

    by Karolien Wellekens, Maarten Coemans, Jasper Callemeyn, Evert Cleenders, Tim Debyser, Steffi De Pelsmaeker, Marie-Paule Emonds, Priyanka Koshy, Dirk Kuypers, Angelica Pagliazzi, et al.


  • Sensitive HLA antibody testing and the risk of antibody‐mediated rejection and graft failure

    by Tim Debyser, Jasper Callemeyn, Maarten Coemans, Johan Kerkhofs, Priyanka Koshy, Dirk Kuypers, Aleksandar Senev, Anat R. Tambur, Elisabet Van Loon, Karolien Wellekens, et al.

    Solid phase detection and identification of HLA antibodies in kidney transplantation currently relies on single antigen bead (Luminex®) assays, which is more sensitive than the previously used enzyme‐linked immunosorbent assays (ELISA). To evaluate the impact of more sensitive HLA testing on antibody‐mediated rejection (AMR) occurrence and allograft survival, we analysed 1818 renal allograft recipients transplanted between March 2004 and May 2021. In 2008, solid phase testing switched from ELISA to Luminex. We included 393 (21.6%) transplantations before and 1425 (78.4%) transplantations after transition from ELISA‐ to Luminex‐based testing. For this study, bio‐banked ELISA era samples were tested retrospectively with Luminex. Significantly less pretransplant DSA were found in patients transplanted with pre‐existing HLA antibodies in the Luminex (109/387) versus the ELISA period (43/90) (28% vs. 48%, p < 0.01). Throughout histological follow‐up, 169 of 1818 (9.3%) patients developed AMR. After implementing Luminex‐based testing, the rate of AMR significantly decreased (p = 0.003). However, incidence of graft failure did not significantly differ between both eras. In conclusion, less patients with pretransplant DSA were transplanted since the implementation of Luminex HLA testing. Transition from ELISA‐ to Luminex‐based HLA testing was associated with a significant decrease in AMR occurrence post‐transplantation. Since the decline of AMR did not translate into improved graft survival, Luminex‐based testing has the added value of preventing low‐risk AMR cases. Therefore, Luminex' high sensitivity must be balanced against waiting time for a suitable organ.